Protalex Announces Two Posters Accepted for Presentation at 2013 American … – Wall Street Journal

Protalex Announces Two Posters Accepted for Presentation at 2013 American …
Wall Street Journal
The complete abstracts for the posters can be accessed in the Science section of the Company’s website at www.protalex.com.

Source: online.wsj.com

FOR IMMEDIATE RELEASE

Contact:

LHA

Anne Marie Fields

afields@lhai.com

212.838.3777

PROTALEX ANNOUNCES TWO POSTERS ACCEPTED FOR PRESENTATION AT 2013 AMERICAN

COLLEGE OF RHEUMATOLOGY ANNUAL MEETING

SUMMIT, N.J. (September 30, 2013)

 

– Protalex, Inc. (OTCBB: PRTX), a clinical-stage biopharmaceutical

company, today announced that two posters relating to PRTX-100, the Company’s investigational drug,

were accepted for presentation at the 2013 American College of Rheumatology ARHP Annual Meeting,

to be held at the San Diego Convention Center from October 25 – 30, 2013. PRTX-100 is a highly purified

form of Staphylococcal Protein A, an immunodulatory bacterial protein. The complete abstracts for the

posters can be accessed in the Science section of the Company’s website at

 

www.protalex.com.

The posters will be presented by Edward Bernton, M.D., Protalex’s Chief Scientific Officer and a coauthor

of both posters, and will be available for viewing as follows:

Poster Title:

 

"Treatment With Staphylococcal Protein A, Which Is Immuno-Modulatory In The

Murine Collagen Arthritis Model, Does Not Increase Infection Severity In Murine

Listeria Or Candida Challenge Models, In Contrast To Anti-TNF Treatment”

Session Name: Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis II

Date and Session Time: Tuesday, October 29, 2013, 8:30 AM – 4:00 PM

Location: Exhibit Hall B2-C-D

Presentation Number: 1843

Poster Title:

 

“Complement Activation and Anaphylatoxin Generation Response to

Staphylococcal Protein A Exposure: Ex Vivo and In Vivo Human Studies”

Session Name: Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis II

Date and Session Time: Tuesday, October 29, 2013, 8:30 AM – 4:00 PM

Location: Exhibit Hall B2-C-D

Presentation Number: 1865

Dr. Bernton commented, “We are pleased to be able to present data for the second consecutive year at

this major U.S. meeting of rheumatology specialists. Poster 1843 compares treatment of mice with

PRTX-100 and two drugs, which like many anti-TNF therapies neutralize tumor necrosis factor. PRTX-100

and the anti-TNF treatments all have been shown to decrease joint inflammation in a mouse model of

autoimmune inflammatory arthritis. However, when mice are infected with either a bacterial pathogen

called listeria or a fungal pathogen, the anti-TNF therapies increase the severity and lethality of the

infection, whereas PRTX-100 treatment does not.

“In addition, Poster 1865 addresses a more fundamental scientific question. PRTX-100, which binds

antibody molecules, has the ability to link them together into what are called

 

immune complexes. Some

larger immune complexes can activate pro-inflammatory defense proteins called

 

the complement

system

 

. We investigated the activation of complement by adding PRTX-100 to human serum or blood,

as well as in blood samples from patients dosed with PRTX-100 in our Phase 1b clinical trial. These

studies showed no evidence that PRTX-100 caused significant complement activation, increasing our

understanding of the safety profile of this novel drug candidate.”

The ACR/ARHP Annual Meeting

The ACR/ARHP Annual Meeting is the premier event for anyone involved in the research or delivery of

rheumatologic care or services. At ACR/ARHP rheumatology leaders from around the world gather to

discuss the latest science, research and treatment in rheumatology. Innovative sessions, groundbreaking

scientific abstracts, educational programs and popular session formats, as well as hands-on skill

training sessions are just some of the highlights of the meeting.

About Protalex, Inc.

Protalex, Inc. is a clinical-stage biopharmaceutical company focused on the development of a class of

drugs for treating autoimmune and inflammatory diseases, including rheumatoid arthritis. Protalex’s

lead product, PRTX-100, is a formulation of a proprietary, highly purified form of Staphylococcal Protein

A, which is an immune modulating protein produced by bacteria. Protalex has completed a Phase 1b

clinical trial in adult patients with active rheumatoid arthritis in South Africa which demonstrated that

PRTX-100 was generally safe and well tolerated at all dose levels, and at the higher doses, more patients

showed improvement in their CDAI (Clinical Disease Activity Index) for RA than did patients at the lower

dose or placebo cohorts. PRTX-100 has the ability, at very low concentrations, to bind to human Blymphocytes

and macrophages and to activate processes that mediate inflammation in certain

autoimmune diseases. Laboratory studies indicate that the mechanism involves interaction with specific

immunologic signaling pathways.

Forward-Looking Statements

Statements in this press release, including with respect to the outcome of the Phase 1b study described, that are

not statements of historical or current fact constitute "forward-looking statements." Such forward-looking

statements involve known and unknown risks, uncertainties and other unknown factors that could cause the

Company’s actual operating results to be materially different from any historical results or from any future results

expressed or implied by such forward-looking statements. In addition to statements that explicitly describe these

risks and uncertainties, readers are urged to consider statements that contain terms such as "believes," "belief,"

"expects," "expect," "intends," "intend," "anticipate," "anticipates," "plans," "plan," to be uncertain and forwardlooking.

The forward-looking statements contained herein are also subject generally to other risks and

uncertainties that are described from time to time in the Company’s filings with Securities and Exchange

Commission.

# # #

See on Scoop.it(Academic & Scientific) Poster Presentation

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: